Sona Nanotech: Using Nanotechnology to Transform Diagnostics and Healthcare

Sona Nanotech Inc. (CSE:SONA) has launched its campaign on the Investing News Network’s life science channel.

Sona Nanotech Inc. (CSE:SONA) has launched its campaign on the Investing News Network’s life science channel.

Sona Nanotech is a nanotechnology life science company that has developed two innovative gold nanorod products: GeminiTM and OmniTM. Gemini is a CTAB-free gold nanorod product that enables multiplexing of lateral flow diagnostic tests for multiple analytes on just one device, returning accurate results in only minutes. Lateral flow diagnostic testing is used to confirm the absence or presence of analytes or contaminants. The tests are commonly found in human health point-of-care testing and can be applied to a number of different industries due to their versatility.

OmniTM is another innovative gold nanorod product designed by Sona Nanotech in order to be used In-vivo (inside cells) for medical applications including drug delivery, photothermal therapy and cell imaging. In addition to its gold nanorod products, Sona Nanotech offers additional services that utilize the same technology including conjugation services, lateral flow test development and lateral flow test production.

Sona Nanotech’s company highlights include the following:

  • Sona Nanotech has developed two gold nanorod products: GeminiTM and OmniTM.
  • Sona’s CTAB-free GeminiTM is a CTAB-free gold nanorod product that enables multiplexing of lateral flow diagnostic tests for multiple analytes on just one device that provides accurate results in minutes.
  • GeminiTM rods offers numerous advantages over current labels when incorporated into lateral flow assays, including multiple distinct colors for simple identification and quantification measurement as well as increasing test performance by improving limits of detection and time to results
  • OmniTM, a non-toxic gold nanorod, which is also CTAB-free, that could be used In-vivo (inside cells) for medical applications such as drug delivery, photothermal therapy and cell imaging.
  • Sona Nanotech generates revenue through licenses and royalties as well as reagent sales, contract development services and test manufacturing.
  • The company expects to generate $35.9 million in revenue by 2025 through its four revenue channels.
  • Continuous product development is a cornerstone of Sona Nanotech’s business model and has led to numerous partnerships and collaborations.
  • The company has partnerships in place with Expedeon, Romer labs, Soma Bioscience, Bond Digital Health, Cape Breton University, Operon and Anteo Technologies, among others.

Click here to learn more about Sona Nanotech Inc. (CSE:SONA) and to request an investor presentation.

Featured
Le 29 septembreSeptember 2021) Love Pharma Inc., the issuer resulting from a Fundamental Change of Glenbriar Technologies Inc. has been approved for listing. Listing and disclosure documents will be available at on the trading date. Love Pharma Inc., is a specialized health and wellness company offering pharmaceutical and therapeutic products with proven technologies for which it has the exclusive rights to produce, ...

Le 29 septembreSeptember 2021) Love Pharma Inc., the issuer resulting from a Fundamental Change of Glenbriar Technologies Inc. (GTI.X), has been approved for listing.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

read more Show less

How to Invest in Life Science

How to Invest in Life Science

A breakdown of everything to know about how to invest in life science — from biotech and pharmaceuticals to medical devices and genetics.

The overarching term “life science” refers to the study of living organisms and life processes. Given the sector’s broad reach, many investors aren’t sure exactly how to invest in life science. 

To start, it’s important to understand that the industry encompasses the fields of biotechnology, pharmaceuticals, medical devices and genetics, to name just a few. Companies within each subsector are involved in researching and developing innovative products, advancing technology and striving towards drug or device commercialization by way of clinical trials and patent applications.

read more Show less
Sixth Wave Innovations Inc. is pleased to announce the finalization of a commercial system design for Affinity™ cannabis purification technology. SIXW is contracted to deliver three units to Oregon-based producer Green Envy Extracts after successful field trials beginning in the fall of 2021.The Affinity™ System is a leading-edge purification process that will allow cannabis producers to deliver a product with ...

Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) ("Sixth Wave", "SIXW" or the "Company") is pleased to announce the finalization of a commercial system design for Affinity™ cannabis purification technology. SIXW is contracted to deliver three units to Oregon-based producer Green Envy Extracts (the "Customer") after successful field trials beginning in the fall of 2021.

The Affinity™ System is a leading-edge purification process that will allow cannabis producers to deliver a product with the highest possible THC/cannabinoid purity with greater consistency that consumers demand. Affinity™ machines will use Sixth Wave's breakthrough nanotechnology to significantly increase yields for producers by reducing the amount of cannabis lost through traditional methods in faster times with lower costs.

read more Show less

MARKETS

Markets
TSX20464.60-195.39
TSXV917.92-21.52
DOW34022.04-461.68
S&P 5004513.040.00
NASD15254.05-283.64
ASX7235.90-20.10

COMMODITIES

Commodities
Gold1776.45-5.38
Silver22.38+0.02
Copper4.25+0.01
Palladium1717.50-33.50
Platinum942.00+6.00
Oil65.32-0.25
Heating Oil2.080.00
Natural Gas4.15-0.10